414 results match your criteria: "Department of Clinical Infectious Diseases[Affiliation]"
Sci Rep
January 2024
Administrative Office, University of Toyama, Toyama, Japan.
Eur J Clin Microbiol Infect Dis
March 2024
Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, 2630 Sugitani, Toyama, 930-0194, Japan.
Purpose: During the last decade, the incidence of anaerobic bacteremia (AB) has been increasing. Patients with AB may develop complex underlying diseases, which can occasionally be accompanied by fatal or fulminant outcomes. However, the risk factors for AB-related mortality remain unclear.
View Article and Find Full Text PDFHeliyon
January 2024
Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, 480-1195, Japan.
Despite advances in medical technology, lung cancer still has one of the highest mortality rates among all malignancies. Therefore, efforts must be made to understand the precise mechanisms underlying lung cancer development. In this study, we conducted lung and gut microbiome analyses and a comprehensive lipid metabolome analysis of host tissues to assess their correlation.
View Article and Find Full Text PDFJ Infect Chemother
June 2024
Medical Writing Department, Kowa Company, Ltd., 4-14, 3-Chome, Nihonbashi-Honcho Chuo-ku, Tokyo, 103-8433, Japan.
Background: Ivermectin is an antiparasitic drug administered to hundreds of millions of people worldwide. Fundamental research suggests that ivermectin is effective against coronavirus disease 2019 (COVID-19); therefore, we investigated the efficacy and safety of ivermectin as a COVID-19 treatment option.
Methods: This multi-regional (Japan and Thailand), multicenter, placebo-controlled, randomized, double-blind, parallel-group, Phase III study evaluated the efficacy and safety of ivermectin in patients with mild COVID-19 (IVERMILCO Study).
Eur J Clin Microbiol Infect Dis
March 2024
Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata Nagakute-Shi, Aichi, 480-1195, Japan.
J Infect Chemother
July 2024
Department of Clinical Infectious Diseases, Kochi Medical School, Kochi University, Japan. Electronic address:
Infect Drug Resist
December 2023
Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
Infect Drug Resist
November 2023
Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
Lancet Microbe
February 2024
Microbiology and Infection Research Group, Department of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, UK.
Antibiotics (Basel)
October 2023
Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama 930-0194, Japan.
Panton-Valentine leucocidin (PVL)-negative community-associated methicillin-resistant (CA-MRSA) was originally disseminated in Japan and has since replaced healthcare-associated MRSA (HA-MRSA). However, the clinical characteristics of CA-MRSA bacteremia (CA-MRSAB) compared with those of HA-MRSA bacteremia (HA-MRSAB) are unknown. We aim to clarify differences and investigate associations between the clinical manifestations and virulence genes associated with plasma-biofilm formation in PVL-negative CA-MRSA.
View Article and Find Full Text PDFOpen Forum Infect Dis
October 2023
Department of Clinical Infectious Diseases, Hammersmith Hospital, Imperial College Healthcare National Health Service Trust, London, United Kingdom.
Awareness of neurological sequelae of dengue fever is increasing. However, as this case illustrates, there is a diagnostic conundrum in determining whether certain features are in keeping with dengue encephalopathy or dengue encephalitis. Further consensus is required.
View Article and Find Full Text PDFJ Infect Chemother
March 2024
Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan. Electronic address:
Am J Infect Control
April 2024
Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan; Department of Infection Prevention and Control, Aichi Medical University Hospital, Aichi, Japan. Electronic address:
Background: Current models for predicting Clostridioides difficile infection (CDI) recurrence rates have a limited capacity to account for important risk factors. This study developed a clinical prediction rule for CDI recurrence.
Methods: This retrospective cohort study evaluated 209 patients with CDI at a university hospital in Japan.
Open Forum Infect Dis
October 2023
Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Background: Mucormycosis is a potentially fatal fungal infection, and there is limited information on its precise epidemiology and treatment practices, including the optimal dosage of liposomal amphotericin B.
Methods: A retrospective, multicenter, nationwide analysis of 82 proven and probable cases of mucormycosis was performed. Cases between 2015 and 2022 were collected from 51 hospitals in Japan by hematologists and infectious disease specialists.
Viruses
September 2023
Department of Clinical Infectious Diseases, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute-shi 480-1195, Aichi, Japan.
The coronavirus disease (COVID-19) pandemic continues to threaten global public health. Remdesivir and monoclonal antibodies have shown promise for COVID-19 treatment of patients who are immunocompromised, including those with cancer, transplant recipients, and those with autoimmune disorder. However, the effectiveness and safety of this combination therapy for patients who are immunosuppressed remain unclear.
View Article and Find Full Text PDFFront Immunol
September 2023
Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Background: Immune response indicators in the early phase of COVID-19, including interferon and neutralizing responses against SARS-CoV-2, which predict hypoxemia remains unclear.
Methods: This prospective observational study recruited patients hospitalized with COVID-19 (before emergence of omicron variant). As the immune indicators, we assessed the serum levels of IFN-I/III, IL-6, CXCL10 and VEGF, using an ELISA at within 5 days after the onset of symptoms, and serum neutralizing responses using a pseudovirus assay.
J Infect Chemother
January 2024
Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Introduction: Infection and mortality rates caused by the coronavirus infectious disease 2019 (COVID-19) pandemic were high. However, the influence of the COVID-19 pandemic on the clinical burden in medical facilities remains to be clarified in Japan.
Materials And Methods: This study used a questionnaire-based web survey to clarify how the COVID-19 pandemic affected infectious disease practice and infection control.
Cureus
August 2023
Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, JPN.
Background infection (CDI) recurrence is a public health concern as well as a health economic burden. Bezlotoxumab treatment is one way to prevent recurrence; however, its clinical results have not been reported in Japan. Therefore, we investigated the efficacy and safety of bezlotoxumab in patients with CDI at a university hospital in Japan and compared them with previously reported findings.
View Article and Find Full Text PDFMed Mycol J
September 2023
Department of Clinical Infectious Diseases, Aichi Medical University.
The human body is host to a large number of commensal microbial species such as bacteria, fungi, and viruses. Among these, the human mycobiome is often neglected as a potential cause of disease, as it is thought to be comparatively much less abundant and less diverse than the human bacteriome. Additionally, most fungi are not easily cultured, even in specific media.
View Article and Find Full Text PDFAntibiotics (Basel)
August 2023
Department of Clinical Infectious Diseases, Aichi Medical University, 1-1 Yazakokarimata Nagakute-shi, Aichi 480-1195, Japan.
J Infect Chemother
December 2023
Disease Control and Prevention Center/Travel Clinic, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
J Infect Chemother
December 2023
Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
We investigated the epidemiology and antimicrobial susceptibility profiles of seven major Gram-negative bacilli (Escherichia coli, Klebsiella spp., Enterobacter spp., Pseudomonas aeruginosa, Acinetobacter spp.
View Article and Find Full Text PDFJ Orthop Surg Res
August 2023
Department of Clinical Infectious Diseases, Aichi Medical University, 1-1, Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Background: Accurate diagnosis of prosthetic joint infection (PJI) enables early and effective treatment. However, there is currently no gold standard test for microbial detection of PJI and traditional synovial fluid culture is relatively insensitive. Recently, it has been reported that sonicating fluid culture and next-generation sequencing (NGS) improve microbial detection rates.
View Article and Find Full Text PDFMycoses
December 2023
Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan.
Background: The optimal timing for therapeutic drug monitoring (TDM) of voriconazole in Asians, who have higher rates of poor metabolisers than non-Asians, is unclear. This can cause unexpectedly high concentrations and delays in reaching steady-state levels.
Objectives: To determine the appropriate timing of TDM in Japanese patients receiving voriconazole.